Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$63.28

-9.7 (-13.29%)

16:14
12/02/19
12/02
16:14
12/02/19
16:14

Arrowhead announces offering of 4M shares of common stock

Arrowhead Pharmaceuticals announced its intention to offer and sell 4M shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes. Goldman Sachs, Jefferies, and Piper Jaffray are acting as bookrunning managers for the offering, Cantor Fitzgerald is acting as passive joint bookrunner for the offering, and Robert W. Baird and B. Riley FBR are acting as co-managers for the offering.

  • 03

    Dec

ARWR Arrowhead
$63.28

-9.7 (-13.29%)

11/25/19
BARD
11/25/19
UPGRADE
Target $70
BARD
Outperform
Arrowhead upgraded to Outperform after Medicines Company takeover at Baird
As previously reported, Baird analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals (ARWR) to Outperform from Neutral with a price target of $70, up from $39, after Medicines Company (MDCO) announced a definitive agreement to be acquired by Novartis (NVS). That deal forces Kumar to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease, the analyst tells investors. Given the early positive efficacy for Arrowhead's ANGPTL3 and APOC3 RNAi drugs presented at the American Heart Association meeting, Kumar believes these programs have "the chance to dominate the ANGPTL3 and APOC3 landscapes," though cautions both are "quite early."
11/25/19
11/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deckers Brands (DECK) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying the stock's upside guidance potential amid improving weather outlook for the 2nd half of FY20 and also cites the company's "compelling" portfolio structure along with its "cash cow" UGG brand. 2. Wendy's (WEN) upgraded to Buy from Hold at Stifel with analyst Chris O'Cull saying he left recent management meetings with greater confidence in the company's sales and EBITDA drivers over the next few years, especially the breakfast launch planned for 2020. 3. Hasbro (HAS) upgraded to Buy from Neutral at UBS with analyst Arpine Kocharyan saying expectations for the company have seen a "meaningful reset" after a weak Q3 results, but he sees upside in the stock thanks to the better than expected revenue and the cost synergies from Entertainment One acquisition, along with the momentum of its gaming portfolio. 4. Nvidia (NVDA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Joseph Moore saying both of Nvidia's gaming and data center segments fell short of expectations over the course of 2019, but investments made this year in the gaming business should pay off in 2020 while recent Cloud commentary indicates that the inflection in "conversational AI" is real and new Nvidia products should ease concerns about competition in the data center segment. 5. Arrowhead (ARWR) upgraded to Outperform from Neutral at Baird with analyst Madhu Kumar saying Medicines Company's (MDCO) announcement of a definitive agreement to be acquired by Novartis (NVS) forces him to re-evaluate Arrowhead' RNAi platform, which is heavily levered to lipid-modifying RNAi drugs for cardiovascular disease. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/26/19
PIPR
11/26/19
NO CHANGE
Target $72
PIPR
Overweight
Arrowhead price target raised to $72 from $54 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $72 from $54 and reiterates an Overweight rating on the shares following last night's results. The company expects to have three pivotal Phase III trials underway in 2020, Tenthoff tells investors in a research note. He believes Arrowhead's RNAi will address both orphan and broader cardiovascular indications characterized by high triglycerides.
11/27/19
RILY
11/27/19
NO CHANGE
Target $83
RILY
Buy
Arrowhead price target raised to $83 from $59 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $83 from $59 while maintaining a Buy rating on the shares. The analyst believes the company has built a "unique" position in RNAi-based therapies.

TODAY'S FREE FLY STORIES

AVGO

Broadcom

$327.39

7.53 (2.35%)

08:46
12/13/19
12/13
08:46
12/13/19
08:46
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
12/13/19
12/13
08:45
12/13/19
08:45
General news
U.S. import prices increased 0.2% »

U.S. import prices…

AMC

AMC Entertainment

$8.29

0.12 (1.47%)

, SCO

Scor ADR

$13.01

-0.21 (-1.59%)

08:45
12/13/19
12/13
08:45
12/13/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

AMC

AMC Entertainment

$8.29

0.12 (1.47%)

SCO

Scor ADR

$13.01

-0.21 (-1.59%)

PLCE

Children's Place

$58.26

4.46 (8.29%)

CHWY

Chewy

$27.95

1.08 (4.02%)

TLRY

Tilray

$18.87

0.68 (3.74%)

BLDP

Ballard Power

$6.17

0.095 (1.56%)

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$12.68

0.11 (0.88%)

GTT

GTT Communications

$12.01

-0.36 (-2.91%)

Z

Zillow

$42.51

-0.22 (-0.51%)

SVXY

ProShares Short VIX Short-Term Futures

$63.16

1.65 (2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

08:45
12/13/19
12/13
08:45
12/13/19
08:45
General news
U.S. retail sales increased 0.2% in November, and were up 0.1% excluding autos »

U.S. retail sales…

08:45
12/13/19
12/13
08:45
12/13/19
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

VCTR

Victory Capital

$21.68

0.235 (1.10%)

08:44
12/13/19
12/13
08:44
12/13/19
08:44
Downgrade
Victory Capital rating change  »

Victory Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$5.08

0.16 (3.25%)

08:43
12/13/19
12/13
08:43
12/13/19
08:43
Conference/Events
Corbus Pharmaceuticals to hold a webinar »

Expert panel discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

EV

Eaton Vance

$47.08

0.395 (0.85%)

08:42
12/13/19
12/13
08:42
12/13/19
08:42
Upgrade
Eaton Vance rating change  »

Eaton Vance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTMI

TTM Technologies

$13.79

0.19 (1.40%)

08:41
12/13/19
12/13
08:41
12/13/19
08:41
Upgrade
TTM Technologies rating change  »

JPMorgan upgrades TTM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$94.63

0.16 (0.17%)

08:39
12/13/19
12/13
08:39
12/13/19
08:39
Conference/Events
Arthur J. Gallagher to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

NEWR

New Relic

$66.87

0.86 (1.30%)

08:38
12/13/19
12/13
08:38
12/13/19
08:38
Recommendations
New Relic analyst commentary  »

Morgan Stanley came way…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMK

AssetMark Financial

$27.31

0.42 (1.56%)

08:38
12/13/19
12/13
08:38
12/13/19
08:38
Upgrade
AssetMark Financial rating change  »

JPMorgan upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$259.14

0.71 (0.27%)

08:38
12/13/19
12/13
08:38
12/13/19
08:38
Conference/Events
Lennox to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

VIAC

ViacomCBS

$37.79

0.52 (1.40%)

08:36
12/13/19
12/13
08:36
12/13/19
08:36
Initiation
ViacomCBS initiated  »

ViacomCBS reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$2.23

0.12 (5.69%)

08:35
12/13/19
12/13
08:35
12/13/19
08:35
Hot Stocks
Cellectar Biosciences presents data on CLR 2000045 at AACR symposium »

Cellectar Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCFT

OneConnect

$0.00

(0.00%)

08:35
12/13/19
12/13
08:35
12/13/19
08:35
Syndicate
OneConnect 31.2M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

, MRK

Merck

$88.95

0.6 (0.68%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Hot Stocks
OncoSec reports interim results from KEYNOTE-890 study »

OncoSec announced interim…

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

MRK

Merck

$88.95

0.6 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

CFX

Colfax

$35.74

0.6 (1.71%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Conference/Events
Colfax to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Hot Stocks
Sarepta announces $250M of non-dilutive senior secured loan financing »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ATNX

Athenex

$16.94

-0.36 (-2.08%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Athenex announces results from Phase III trial of oral paclitaxel »

Athenex announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PFE

Pfizer

$38.54

0.3 (0.78%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Pfizer announces CHMP recommendation for approval of Vyndaqel »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TREE

LendingTree

$293.67

-13 (-4.24%)

08:31
12/13/19
12/13
08:31
12/13/19
08:31
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$31.01

0.82 (2.72%)

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Conference/Events
Unum Group to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Options
One option delisting on December 13th »

Option delistings…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.